Jump to content
SCLERO.ORG
Sclero Forums

Search the Community

Showing results for tags 'pulmonary fibrosis'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

  1. Progressive interstitial lung disease in patients with systemic sclerosis–associated interstitial lung disease (SSc–ILD) in the EUSTAR database. SSc-ILD shows a heterogeneous and variable disease course, and thus monitoring all patients closely is important. PubMed, Ann rheumatologist Dis, 2021 Feb;80(2):219-227. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Osteopontin Protein May Be Cause of Lung Scarring in Scleroderma. Osteopontin may be driving scarring of lung tissue in people with scleroderma associated with interstitial lung disease, a study suggests. Scleroderma News, 12/22/2020. (Also see Pulmonary Fibrosis Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Serum markers of pulmonary epithelial damage in systemic sclerosis–associated interstitial lung disease (SSc-ILD) and disease progression. Our results suggest serum KL-6 predicts decline in lung function in SSc, suggesting its clinical utility in risk stratification for progressive SSc-ILD. PubMed, Respirology, 12/17/2020. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Increased expression of interferon regulated and antiviral response genes in CD31+/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease. These observations suggest that interferon-induced and antiviral response proteins may participate in the pathogenesis of SSc vasculopathy and SSc-ILD. PubMed, Clin Exp Rheumatol, 11/17/2020. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. Reagents that disrupt the interaction of TL1A with DR3 then have the potential to prevent deregulated tissue cell activity in lung diseases that involve fibrosis and remodeling. PubMed, J Immunol, 2020 Sep 21;ji2000665. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (Ssc-ILD). Our study cohort found that a worsening esophageal diameter was a predictor of progression of lung fibrosis determined by HRCT score in early SSc-ILD. PubMed, Clin Rheumatol, 08/15/2020. (Also see Correlation between Pulmonary Fibrosis and other Diseases or Complications and Gastrointestinal Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for
  7. Bioactive Plasma Mitochondrial DNA (mtDNA) Is Associated With Disease Progression in Scleroderma Associated Interstitial Lung Disease (SSc-ILD). These findings demonstrate an unrecognized connection between extracellular vesicles-encapsulated mtDNA, clinical outcomes, and intracellular DNA-sensing pattern recognition receptors activation in SSc-ILD. PubMed, Arthritis Rheumatol, 06/30/2020. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Systemic sclerosis (SSc) and the COVID-19 pandemic: World preliminary advice for patient management. SSc patients are a great challenge for the physician to achieve an effective protective strategy or, when infected, to optimise a real-time treatment as suggested by the rapidly evolving guidelines. BMJ Journals, Ann rheumatologist Dis, 04/29/2020. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Short or long sleep associated with Idiopathic Pulmonary Fibrosis. The study reveals that targeting the body clock reduces fibrosis in vitro, revealing a potential target for this incurable disease. University of Manchester, 12/30/2019. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Defining genetic risk factors for scleroderma-associated interstitial lung disease (SSc-ILD) : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease. Further work is required to understand the genetic basis of lung fibrosis in association with scleroderma. PubMed, Clin Rheumatol, 01/08/2020. (Also see Pulmonary Fibrosis Diagnosis and Genetics) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Interferon Lambda (IFNL3) genotype is associated with pulmonary fibrosis (PF) in patients with systemic sclerosis (SSc). IFNL3 serum levels and the genetic variant known to be associated with liver fibrosis are similarly linked to PF, but not to worsening of skin fibrosis in SSc. PubMed, Sci Rep, 2019 Oct 16;9(1):14834. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. Esophageal body dysmotility on HRM positively correlates with the presence of interstitial lung disease. PubMed, Clin Rheumatol, 11/11/2019. (Also see Dysmotility Syndrome and Correlation between Pulmonary Fibrosis and other Diseases) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Increased prevalence of small airways dysfunction in patients with systemic sclerosis (SSc) as determined by impulse oscillometry. A full assessment of lung function in SSc patients should include impulse oscillometry as a complementary technique, due to potential clinical and therapeutic implications. PubMed, Rheumatology (Oxford), 08/22/2019. (Also see Pulmonary Fibrosis Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. CCL24 plays an important role in pathological processes of skin and lung inflammation and fibrosis. PubMed, Ann rheumatologist Dis, 05/25/2019. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Anti-C1q autoantibodies (autoAbs) are frequently detected in patients with systemic sclerosis (SSc) associated with pulmonary fibrosis. Anti-C1q autoAbs were frequently detected in patients with SSc, and their high levels predict the co–occurrence of pulmonary fibrosis or pulmonary arterial hypertension. PubMed, Br J Dermatol, 03/15/2019. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Further investigation into the mechanistic role of monocytes in fibrosis might lead to insights that assist the development of new therapies. PubMed, Lancet Respir Med, 03/29/2019. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. Short–term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) predicts long–term survival in two independent clinical trial cohorts. These findings suggest that short–term changes in surrogate measures of SSc–ILD progression may have important effects on long–term outcomes. PubMed, Ann rheumatologist Dis, 11/08/2018. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. Recent progress in systemic sclerosis–interstitial lung disease (SSc–ILD). The implications of much of this ongoing work is our ability to identify those patients at risk for progression, and to offer novel therapies that can limit the progression of inflammatory and fibrotic lung disease. PubMed, Curr Opin Rheumatol, 2018 Nov;30(6):570-575. (Also see Pulmonary Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Prediction of therapeutic response before and during I.v. cyclophosphamide (IVCY) pulse therapy for interstitial lung disease in systemic sclerosis (SSc–ILD): A longitudinal observational study. ILD severity/activity before treatment and variability of serum Krebs von den Lungen-6, surfactant protein D levels during treatment may be useful to predict therapeutic effects of IVCY on SSc–ILD. PubMed, J Dermatol, 10/05/2018. (Also see Pulmonary Fibrosis Treatments) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other
  20. Radiological images of interstitial pneumonia in mixed connective tissue disease (MCTD) compared with scleroderma (SSc) and polymyositis/dermatomyositis(PM/DM). HRCT images in MCTD patients can be classified as SSc pattern or PM/DM pattern. PubMed, Eur J Radiol, 2018 Oct;107:26-32. (Also see Correlation between Pulmonary Fibrosis and other Diseases, Mixed Connective Tissue Disease and Dermatomyositis and Polymyositis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  21. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. The results suggest that systemic scleroderma patients with high TLR4 activity might show optimal therapeutic response to selective inhibitors of MD2/TLR4 complex formation. PubMed, JCI Insight, 2018 Jul 12;3(13). (Also see Fibroblasts, Skin Fibrosis and Pulmonary Fibrosis Research) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  22. Association of serum homocysteine level and lung involvement in systemic sclerosis (SSc). It seems that the serum level of homocystein has a minor role in the lung involvement of SSc patients or its effects are modified by other factors. PubMed, Curr Rheumatol Rev, 06/28/2018. (Also see Pulmonary Fibrosis Disease Correlations) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  23. CT Features of the Usual Interstitial Pneumonia (UIP) Pattern: Differentiating Connective Tissue Disease–Associated Interstitial Lung Disease (CTD–ILD) From Idiopathic Pulmonary Fibrosis (IPF). Although UIP is usually associated with IPF, the index of suspicion for CTD-ILD should be raised in the care of patients with any of the three CT signs. PubMed, AJR Am J Roentgenol, 2018 Feb;210(2):307-313. (Also see Correlation between Pulmonary Fibrosis and other Diseases) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and o
  24. Factors associated with the 6–minute walk distance (6MWD) in patients with systemic sclerosis (SSc). During SSc, the 6MWD is independently associated with initial HR and HR variation; suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):279. (Also see Pulmonary Fibrosis Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  25. Cyclophosphamide for connective tissue disease–associated interstitial lung disease. Researchers may consider comparing cyclophosphamide versus antifibrotic agents, or comparing both versus placebo, in particular, for those with evidence of rapidly progressive fibrotic disease, who may benefit the most. PubMed, Cochrane Database Syst Rev, 01/03/2018. (Also see Treatments for Pulmonary Fibrosis: Oral and IV Cyclophosphamide) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...